INDIANAPOLIS, June 11, 2016 /PRNewswire/ -- New data from
a study funded by Eli Lilly and Company (NYSE: LLY) show that how
healthcare professionals and people with diabetes communicate - as
well as the perceived quality of the personal relationship between
the parties - directly impacts knowledge of the disease by
patients, distress related to living with diabetes, important care
activities, such as frequency of self-monitoring blood glucose, and
insulin adherence. Six abstracts from the Multinational
Observational Insulin Progression (MOSA1c) study, which was led by
Harvard-affiliated Brigham and Women's
Hospital, are being presented at the 76th American
Diabetes Association Scientific Sessions in New Orleans.
"We know from many studies that the majority of patients with
type 2 diabetes using insulin are not achieving glycemic control,"
said Seoyoung C. Kim, M.D.,
associate physician at Brigham and Women's Hospital, assistant
professor of medicine at Harvard Medical School and lead
investigator. "While the data from MOSA1c confirms these findings,
more concerning is that despite less than one-third of patients
achieving glycemic control in this two-year observational study,
only about 40 percent of patients with sub-optimal control added
additional diabetes medication. In addition, because the
relationship between patients and healthcare professionals may have
an effect on the amount of distress patients feel and, in some
cases, the level of A1C, we recognize that how we communicate to
patients and how patients receive that communication really
matters."
Data from over 4,200 patients in 18 countries were monitored in
a non-interventional manner for two years across North and
Latin America, Europe, Asia,
and the Middle East. Other
findings included:
- Improvement in the patient-healthcare provider relationship was
associated with a lower level of diabetes-related distress, higher
diabetes knowledge scores, positive attitudes towards self-care,
such as frequency of self-monitoring blood glucose, and higher
self-reported adherence to the prescribed
treatment.1
- Patients who were younger, more highly educated and living in
Asia were found to be more likely
to have their insulin therapy progressed.2
- Younger age, higher baseline A1C level and use of NPH insulin
were significantly associated with a higher A1C level at the
end of the study, adjusted for adherence.3
"MOSA1c provides a broad view of clinical, psychosocial and
health system factors available and will serve to create a greater
understanding of needs within each system," said David Kendall, vice president, Global Medical
Affairs, Lilly Diabetes. "These data can help us better understand
why so many patients using insulin are not achieving glycemic
goals. We know that this is a complex multi-factorial issue and it
is critical to take into account the specific cultural, social and
individual barriers people with diabetes face when adjustment of
insulin therapy is considered most useful."
The results are an important step forward in helping the
diabetes community understand insulin progression to help
healthcare providers determine the right therapies at the right
times for each patient. Given the complexities of available
therapies across the globe, this should be an increasing area of
research focus to help address this overwhelming public health
issue. As a result of these findings, Lilly will be reaching out to
diabetes experts from all regions included in the study in the
coming months in order to gain a broad cross-cultural perspective
on how best to explore the wealth of information from MOSA1c.
About MOSA1c
MOSA1c is a large, comprehensive study
which examined associations between patients'
backgrounds/behaviors, healthcare settings, healthcare provider
relationships and treatment outcomes for type 2 diabetes in a
long-term prospective manner and followed more than 4,000 adults
and 220 healthcare providers in 18 countries around the world. More
than half of the people studied were in emerging markets, where the
need is great and data has been limited. Ages ranged from 20-79 (50
percent male) with a wide range of socioeconomic status, including
education levels, employment and insurance type. The study not only
provides breadth that helps reveal patterns of treatment on a
global scale, but also depth into the lives of the participants
that can make the data truly meaningful.
About Diabetes
Approximately 29 million
Americans4 and an estimated 415 million people worldwide
have type 1 and type 2 diabetes.5 Type 2 diabetes is the
most common type, accounting for an estimated 90 to 95 percent of
all diabetes cases. Diabetes is a chronic disease
that occurs when the body does not either properly produce or use
the hormone insulin.4
About Lilly Diabetes
Lilly has been a global leader in
diabetes care since 1923, when we introduced the world's first
commercial insulin. Today we are building upon this heritage by
working to meet the diverse needs of people with diabetes and those
who care for them. Through research and collaboration, a broad and
growing product portfolio and a continued determination to provide
real solutions—from medicines to support programs and more—we
strive to make life better for all those affected by diabetes
around the world. For more information, visit www.lillydiabetes.com
or follow us on Twitter: @LillyDiabetes.
About Eli Lilly and Company
Lilly is a global
healthcare leader that unites caring with discovery to make life
better for people around the world. We were founded more than a
century ago by a man committed to creating high-quality medicines
that meet real needs, and today we remain true to that mission in
all our work. Across the globe, Lilly employees work to discover
and bring life-changing medicines to those who need them, improve
the understanding and management of disease, and give back to
communities through philanthropy and volunteerism. To learn more
about Lilly, please visit us at www.lilly.com and
newsroom.lilly.com/social-channels.
P-LLY
References
1 Linetsky B, Curtis BH, Rogers JR et al. The effect
of the patient-physician relationship on insulin progression,
diabetes distress and HbA1c control over time: Insights from the
MOSA1c study. Data presented at the 76th American
Diabetes Association Scientific Sessions, New Orleans, LA.
2 Kim SC, Eddings W, Rogers J et al. Effects of
patient, physician and health care environment factors on insulin
progression in patients with T2DM: the MOSA1c study. Data presented
at the 76th American Diabetes Association Scientific
Sessions, New Orleans, LA.
3 He M, Curtis BH, Eddings W et al. Factors
associated with insulin adherence among patients with type 2
diabetes: the MOSA1c study. Data presented at the 76th
American Diabetes Association Scientific Sessions, New Orleans, LA.
4 Centers for Disease Control and Prevention.
National Diabetes Statistics Report, 2014. Available at:
http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf.
October 2014.
5 International Diabetes Federation. IDF Diabetes
Atlas, 7th edn. Brussels,
Belgium: International Diabetes Federation, 2015.
http://www.idf.org/diabetesatlas.
Refer to: Julie Williams,
williams_julie_herrick@lilly.com, 317-627-4056
Photo -
http://photos.prnewswire.com/prnh/20160609/377471-INFO
Logo - http://photos.prnewswire.com/prnh/20031219/LLYLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/new-study-findings-underscore-importance-of-physicianpatient-communication-on-insulin-adherence-and-outcomes-300283292.html
SOURCE Eli Lilly and Company